Cardiovascular Drugs Market Size, Share, Growth Analysis, By Drug Type (Antihypertensive, Anticoagulants), By Disease Indication (Hypertension, Coronary Artery Disease), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2025-2032

Cardiovascular Drugs Market size was valued at USD 169.98 Billion in 2023 and is poised to grow from USD 177.66 Billion in 2024 to USD 253.04 Billion by 2032, growing at a CAGR of 4.52% during the forecast period (2025-2032).

Lack of time and physical activity among walkers has proven to be a growing factor for the cardiovascular drug market. The prevalence of hypertension in the population has increased the risk of cardiovascular disorders, which helps drive the cardiovascular drug market. The long working hours of young people in developing countries put them at increased risk of cardiovascular disorders. A large number of people are believed to have cardiovascular disease, which increases the sales and supply of related drugs. The minimum age for cardiovascular disorders has been reduced to a great extent, which makes a very favourable factor for the growth of the market. 

With the increase in the prevalence of cardiovascular diseases among the people, a rapid growth is observed in the cardiovascular drugs market. As a result of people wrong lifestyle practices and sedentary habits, the number of people suffering from cardiovascular diseases has increased tremendously. Changes in people's eating and drinking habits have also shown a significant impact on the cardiovascular system. The use of advanced technology and drugs in the market for cardiovascular drugs has seen or fallen in developing countries where people's disposable income is very low. Developed countries have a high disposable income that helps the market record a higher income return than they do. The ignorance of the public about the health facilities available to the public causes the treatment of life-threatening conditions of cardiovascular patients to be delayed. This has a direct impact on the cardiovascular drugs market. However, strict drug approval process and side effects of some cardiovascular drugs hamper the growth of global cardiovascular drugs market.